Harrow (NASDAQ:HROW) Coverage Initiated by Analysts at BTIG Research

Research analysts at BTIG Research began coverage on shares of Harrow (NASDAQ:HROW - Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm set a "buy" rating and a $62.00 price target on the stock. BTIG Research's price target points to a potential upside of 104.55% from the company's previous close.

HROW has been the subject of a number of other research reports. HC Wainwright increased their target price on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. B. Riley cut their target price on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, William Blair began coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harrow has an average rating of "Buy" and an average target price of $61.40.

Harrow Stock Performance

HROW traded down $0.85 on Thursday, hitting $30.31. 291,166 shares of the company's stock were exchanged, compared to its average volume of 502,508. Harrow has a twelve month low of $16.87 and a twelve month high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a market cap of $1.11 billion, a PE ratio of -32.24 and a beta of 0.40. The stock has a fifty day moving average of $26.16 and a two-hundred day moving average of $29.51.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. On average, research analysts anticipate that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harrow

Hedge funds have recently bought and sold shares of the stock. Woodmont Investment Counsel LLC raised its position in Harrow by 0.5% during the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock valued at $2,731,000 after purchasing an additional 445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Harrow by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock worth $582,000 after purchasing an additional 585 shares during the last quarter. Swiss National Bank grew its stake in shares of Harrow by 1.0% in the fourth quarter. Swiss National Bank now owns 59,300 shares of the company's stock worth $1,990,000 after purchasing an additional 600 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Harrow in the fourth quarter valued at $25,000. Finally, MetLife Investment Management LLC lifted its holdings in Harrow by 5.7% in the fourth quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock valued at $634,000 after buying an additional 1,026 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.